Hims & Hers Health, Inc.: Jim Cramer Warns ‘The Gravy Train Might Be Over’ After FDA’s Ozempic Update
We recently published a list of Jim Cramer on 10 Stocks With The Biggest Declines Last Week. In this article, we are going to ...
These Stocks Moved the Most Today: Super Micro, Tesla, Nvidia, Home Depot, Palantir, Hims & Hers, MicroStrategy, and More
Super Micro stock slumps with the server maker having until Tuesday to file delayed financial accounts or risk being delisted ...
Stock of the Day: Hims & Hers plunges 27% after saying it will stop selling its Ozempic competitor
With Hims & Hers' main source of growth set to be extinguished, Citi analysts said its full-year guidance appeared ...
Hims & Hers tumbles 27% as investors fear uncertainty without compounded weight-loss drugs
Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.
Hims & Hers Health (NYSE:HIMS) Craters With Weight Loss Drug Issues
It is bad news for telehealth company Hims & Hers Health (HIMS) today as shares plummeted after its earnings report from yesterday and some ...
Hims & Hers stock tumbles
Hims & Hers will stop selling generic semaglutide after the FDA said the shortage of GLP-1 medications is resolved.
NBC Los Angeles9h
Hims & Hers shares plunge 28% on concerns over weight loss business, margins
Hims & Hers on Monday released fourth-quarter results that disappointed on gross margin and sparked concerns about the future ...
Why Hims & Hers (HIMS) Stock Is Tumbling
Hims & Hers (HIMS) stock is sinking 20% today after Eli Lilly (LLY) unveiled significantly cheaper versions of its popular ...
Heard on the Street: Why Hims & Hers Stock Has Further to Fall
Stock in Hims & Hers Health was bound to tumble once it [could no longer sell]( ...
Novo Nordisk Stock Rallies on Weight-Loss Retreat by Hims & Hers
Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...
Novo Nordisk shares are rallying as Hims & Hers’ stock falters. An Ozempic alternative won’t be available for long.
Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...
Novo Nordisk's stock is rallying as Hims & Hers' stock falters. An Ozempic alternative won't be available for long.
Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won't be selling it for much longer. Hims & Hers Health Inc.'s stock plunged last week when the Food ...